Aberrant promoter methylation of SOCS-1 gene may contribute to the pathogenesis of hepatocellular carcinoma: a meta-analysis.
We conducted this meta-analysis of published case-control studies aiming to evaluate the relationship between abnormal suppression of cytokine signaling-1 (SOCS-1) promoter methylation and the risk of hepatocellular carcinoma (HCC). Relevant studies were retrieved from PubMed, Embase, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI) and China Biological Medicine (CBM) databases without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. We calculated odds ratio (OR) and its 95 % confidence interval (95% CI) to estimate the correlations. Sixteen case-control studies with a total of 941 HCC patients and 114 individuals with benign liver diseases met our inclusion criteria. Our results demonstrated that the frequency of SOCS-1 promoter methylation in cancer tissues was significantly higher than in adjacent non-tumorous tissues and benign tissues (cancer tissue vs adjacent tissue: OR=3.05, 95%CI 1.62-5.77, p=0.001; cancer tissue vs benign tissue: OR=11.55, 95%CI 5.93-22.49, p=0.000). Subgroup analyses by ethnicity, detecting method and sample size also suggested that abnormal SOCS-1 promoter methylation was correlated to the risk of HCC in the majority of these subgroups. Our findings provide empirical evidence that abnormal SOCS-1 promoter methylation may contribute to the pathogenesis of HCC. Thus, detection of SOCS-1 promoter methylation may be a valuable diagnostic biomarker for HCC.